Success still eludes pancreatic cancer pipeline
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
Threats to Spinraza are mounting, but Biogen still has cards to play
Competition is looming from Novartis and Roche but the latest results from Spinraza show that Biogen still has a strong case to make for the SMA therapy.
Big hitters eye Sjögren’s syndrome white space
Orencia’s late-stage failure in Sjögren’s has dashed hopes of a therapy soon, but the mid-stage pipeline is crowded, with Novartis, Glaxosmithkline and Galapagos all…
Price fixing case caps a terrible week for generics
Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
Boehringer’s digital drive starts bearing fruit
Less than two years after setting up its BI X digital lab, Boehringer Ingelheim is ready to start clinical trials of a programme monitoring speech patterns to diagnose…
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
A successful Mylan challenge would see generic entry within two years – though Biogen has fought off copycats before.
How to pay for gene therapies in developing nations
With rich countries like the US finding it hard to fund gene therapies, it is worth asking whether these projects will ever reach patients in developing countries. And if…
China’s blueprint for a checkpoint blocker price war
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
Circassia finds a second way to put investors’ money under threat
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.